Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 8/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.45 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.45 |
| ▸ | S1PR2 | O95136 | 3/20 | 0.45 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.44 |
| ▸ | GGPS1 | O95749 | 5/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8624079 | 0.89 | S1PR1 (0.40) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL8621143 | 0.86 | S1PR1 (0.58) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL8619882 | 0.82 | S1PR1 (0.49) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL8620898 | 0.81 | ENPP2 (0.60) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL27768842 | 0.78 | MEN1 (0.50) | — | |
| SCHEMBL14231808 | 0.77 | MEN1 (0.58) | S1PR1S1PR3 | |
| SCHEMBL6288257 | 0.77 | MEN1 (0.55) | — | |
| SCHEMBL8620187 | 0.77 | FDFT1 (0.55) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL8621086 | 0.76 | FDFT1 (0.56) | S1PR1S1PR3S1PR4S1PR2LPAR2 | |
| Potassium SCHEMBL413355 | 0.76 | FDFT1 (0.69) | GGPS1FDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5712396-A | PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS | MAGNIN DAVID R (US) | 1998-01-27 | — | — | US | claimed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | claimed |
| US-5712396-A | PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS | MAGNIN DAVID R (US) | 1998-01-27 | — | — | US | disclosed |
| US-5567841-A | ANTICHOLESTEROL AGENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | disclosed |